124 related articles for article (PubMed ID: 30358997)
1. Design, Synthesis, Molecular Dynamics Simulation, and Functional Evaluation of a Novel Series of 26RFa Peptide Analogues Containing a Mono- or Polyalkyl Guanidino Arginine Derivative.
Alim K; Lefranc B; Sopkova-de Oliveira Santos J; Dubessy C; Picot M; Boutin JA; Vaudry H; Chartrel N; Vaudry D; Chuquet J; Leprince J
J Med Chem; 2018 Nov; 61(22):10185-10197. PubMed ID: 30358997
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of agonist docking in a human GPR103 homology model by site-directed mutagenesis and structure-activity relationship studies.
Neveu C; Dulin F; Lefranc B; Galas L; Calbrix C; Bureau R; Rault S; Chuquet J; Boutin JA; Guilhaudis L; Ségalas-Milazzo I; Vaudry D; Vaudry H; Santos JS; Leprince J
Br J Pharmacol; 2014 Oct; 171(19):4425-39. PubMed ID: 24913445
[TBL] [Abstract][Full Text] [Related]
3. Point-Substitution of Phenylalanine Residues of 26RFa Neuropeptide: A Structure-Activity Relationship Study.
Lefranc B; Alim K; Neveu C; Le Marec O; Dubessy C; Boutin JA; Chuquet J; Vaudry D; Prévost G; Picot M; Vaudry H; Chartrel N; Leprince J
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299587
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for recognition of 26RFa by the pyroglutamylated RFamide peptide receptor.
Jin S; Guo S; Xu Y; Li X; Wu C; He X; Pan B; Xin W; Zhang H; Hu W; Yin Y; Zhang T; Wu K; Yuan Q; Xu HE; Xie X; Jiang Y
Cell Discov; 2024 Jun; 10(1):58. PubMed ID: 38830850
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of a series of analogues of the RFamide-related peptide 26RFa.
Le Marec O; Neveu C; Lefranc B; Dubessy C; Boutin JA; Do-Régo JC; Costentin J; Tonon MC; Tena-Sempere M; Vaudry H; Leprince J
J Med Chem; 2011 Jul; 54(13):4806-14. PubMed ID: 21623631
[TBL] [Abstract][Full Text] [Related]
6. Molecular evolution of GPCRs: 26Rfa/GPR103.
Ukena K; Osugi T; Leprince J; Vaudry H; Tsutsui K
J Mol Endocrinol; 2014 Jun; 52(3):T119-31. PubMed ID: 24532655
[TBL] [Abstract][Full Text] [Related]
7. Rational design of a low molecular weight, stable, potent, and long-lasting GPR103 aza-β3-pseudopeptide agonist.
Neveu C; Lefranc B; Tasseau O; Do-Rego JC; Bourmaud A; Chan P; Bauchat P; Le Marec O; Chuquet J; Guilhaudis L; Boutin JA; Ségalas-Milazzo I; Costentin J; Vaudry H; Baudy-Floc'h M; Vaudry D; Leprince J
J Med Chem; 2012 Sep; 55(17):7516-24. PubMed ID: 22800498
[TBL] [Abstract][Full Text] [Related]
8. A new series of photoactivatable and iodinatable linear vasopressin antagonists.
Carnazzi E; Aumelas A; Barberis C; Guillon G; Seyer R
J Med Chem; 1994 Jun; 37(12):1841-9. PubMed ID: 8021923
[TBL] [Abstract][Full Text] [Related]
9. Fluorinated pseudopeptide analogues of the neuropeptide 26RFa: synthesis, biological, and structural studies.
Pierry C; Couve-Bonnaire S; Guilhaudis L; Neveu C; Marotte A; Lefranc B; Cahard D; Ségalas-Milazzo I; Leprince J; Pannecoucke X
Chembiochem; 2013 Sep; 14(13):1620-33. PubMed ID: 23940098
[TBL] [Abstract][Full Text] [Related]
10. In silico molecular engineering for a targeted replacement in a tumor-homing peptide.
Zanuy D; Flores-Ortega A; Jiménez AI; Calaza MI; Cativiela C; Nussinov R; Ruoslahti E; Alemán C
J Phys Chem B; 2009 Jun; 113(22):7879-89. PubMed ID: 19432404
[TBL] [Abstract][Full Text] [Related]
11. Behavioral effects of 26RFamide and related peptides.
do Rego JC; Leprince J; Chartrel N; Vaudry H; Costentin J
Peptides; 2006 Nov; 27(11):2715-21. PubMed ID: 16730856
[TBL] [Abstract][Full Text] [Related]
12. Arginine mimetics using α-guanidino acids: introduction of functional groups and stereochemistry adjacent to recognition guanidiniums in peptides.
Balakrishnan S; Scheuermann MJ; Zondlo NJ
Chembiochem; 2012 Jan; 13(2):259-70. PubMed ID: 22213184
[TBL] [Abstract][Full Text] [Related]
13. The 26RFa (QRFP)/GPR103 Neuropeptidergic System: A Key Regulator of Energy and Glucose Metabolism.
Devère M; Takhlidjt S; Prévost G; Chartrel N; Leprince J; Picot M
Neuroendocrinology; 2024 Apr; ():1-17. PubMed ID: 38599200
[TBL] [Abstract][Full Text] [Related]
14. Cysteic- and homocysteic acid-S-(aminoiminomethyl) amides: a new class of modified arginines useful in peptide synthesis.
Buchinska TV
J Pept Res; 1999 Mar; 53(3):314-21. PubMed ID: 10231720
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds.
Tamamura H; Araki T; Ueda S; Wang Z; Oishi S; Esaka A; Trent JO; Nakashima H; Yamamoto N; Peiper SC; Otaka A; Fujii N
J Med Chem; 2005 May; 48(9):3280-9. PubMed ID: 15857134
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold l-arginine as amino-peptidase N/CD13 inhibitors.
Mou J; Fang H; Liu Y; Shang L; Wang Q; Zhang L; Xu W
Bioorg Med Chem; 2010 Jan; 18(2):887-95. PubMed ID: 19969464
[TBL] [Abstract][Full Text] [Related]
17. Nη-substituted arginyl peptide inhibitors of protein arginine N-methyltransferases.
Lakowski TM; 't Hart P; Ahern CA; Martin NI; Frankel A
ACS Chem Biol; 2010 Nov; 5(11):1053-63. PubMed ID: 20701328
[TBL] [Abstract][Full Text] [Related]
18. Structure and activity of insulin, XIII. Specificity of the arginine-guanidino group in biologically active tetrapeptides of the insulin sequence B 22-25 (Arg-Gly-Phe-Phe).
Weitzel G; Eisele K; Stock W
Hoppe Seylers Z Physiol Chem; 1975 May; 356(5):583-90. PubMed ID: 1158333
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and structure-activity relationship of a series of arginine aldehyde factor Xa inhibitors. Part 1: structures based on the (D)-Arg-Gly-Arg tripeptide sequence.
Marlowe CK; Sinha U; Gunn AC; Scarborough RM
Bioorg Med Chem Lett; 2000 Jan; 10(1):13-6. PubMed ID: 10636232
[TBL] [Abstract][Full Text] [Related]
20. Diversity-oriented synthesis of azapeptides with basic amino acid residues: aza-lysine, aza-ornithine, and aza-arginine.
Traoré M; Doan ND; Lubell WD
Org Lett; 2014 Jul; 16(13):3588-91. PubMed ID: 24959890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
